Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics

David Gurwitz, David Gurwitz

Abstract

At the time of writing this commentary (February 2020), the coronavirus COVID-19 epidemic has already resulted in more fatalities compared with the SARS and MERS coronavirus epidemics combined. Therapeutics that may assist to contain its rapid spread and reduce its high mortality rates are urgently needed. Developing vaccines against the SARS-CoV-2 virus may take many months. Moreover, vaccines based on viral-encoded peptides may not be effective against future coronavirus epidemics, as virus mutations could make them futile. Indeed, new Influenza virus strains emerge every year, requiring new immunizations. A tentative suggestion based on existing therapeutics, which would likely be resistant to new coronavirus mutations, is to use available angiotensin receptor 1 (AT1R) blockers, such as losartan, as therapeutics for reducing the aggressiveness and mortality from SARS-CoV-2 virus infections. This idea is based on observations that the angiotensin-converting enzyme 2 (ACE2) very likely serves as the binding site for SARS-CoV-2, the strain implicated in the current COVID-19 epidemic, similarly to strain SARS-CoV implicated in the 2002-2003 SARS epidemic. This commentary elaborates on the idea of considering AT1R blockers as tentative treatment for SARS-CoV-2 infections, and proposes a research direction based on datamining of clinical patient records for assessing its feasibility.

Keywords: AT1R blockers; COVID-19 epidemic; SARS-CoV-2; angiotensin-converting enzyme 2 (ACE2); losartan.

Conflict of interest statement

The author declares no potential conflict of interest.

© 2020 Wiley Periodicals, Inc.

References

    1. Beigel, J. H. , Nam, H. H. , Adams, P. L. , Krafft, A. , Ince, W. L. , El‐Kamary, S. S. , & Sims, A. C. (2019). Advances in respiratory virus therapeutics—A meeting report from the 6th isirv Antiviral Group conference. Antiviral Research, 167, 45–67. 10.1016/j.antiviral.2019.04.006
    1. Belongia, E. A. , Skowronski, D. M. , McLean, H. Q. , Chambers, C. , Sundaram, M. E. , & De Serres, G. (2017). Repeated annual influenza vaccination and vaccine effectiveness: Review of evidence. Expert Review of Vaccines, 16(7), 1–14. 10.1080/14760584.2017.1334554
    1. Chen, Y. , Guo, Y. , Pan, Y. , & Zhao, Z. J. (2020). Structure analysis of the receptor binding of 2019‐nCoV. Biochemical and Biophysical Research Communications. 10.1016/j.bbrc.2020.02.071 [Epub ahead of print].
    1. Cheng, Z. J. , & Shan, J. (2020). 2019 Novel coronavirus: Where we are and what we know. Infection. 10.1007/s15010-020-01401-y [Epub ahead of print].
    1. Deppe, S. , Böger, R. H. , Weiss, J. , & Benndorf, R. A. (2010). Telmisartan: A review of its pharmacodynamic and pharmacokinetic properties. Expert Opinion on Drug Metabolism & Toxicology, 6(7), 863–871. 10.1517/17425255.2010.494597
    1. de Wit, E. , van Doremalen, N. , Falzarano, D. , & Munster, V. J. (2016). SARS and MERS: Recent insights into emerging coronaviruses. Nature Reviews. Microbiology, 14(8), 523–534. 10.1038/nrmicro.2016.81
    1. Dimitrov, D. S. (2003). The secret life of ACE2 as a receptor for the SARS virus. Cell, 115(6), 652–653.
    1. Gao, J. , Tian, Z. , & Yang, X. (2020). Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID‐19 associated pneumonia in clinical studies. Bioscience Trends. 10.5582/bst.2020.01047 [Epub ahead of print].
    1. Furuhashi, M. , Moniwa, N. , Mita, T. , Fuseya, T. , Ishimura, S. , Ohno, K. , … Miura, T. (2015). Urinary angiotensin‐converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. American Journal of Hypertension, 28(1), 15–21. 10.1093/ajh/hpu086
    1. Ge, X. Y. , Li, J. L. , Yang, X. L. , Chmura, A. A. , Zhu, G. , Epstein, J. H. , … Shi, Z. L. (2013). Isolation and characterization of a bat SARS‐like coronavirus that uses the ACE2 receptor. Nature, 503(7477), 535–538. 10.1038/nature12711
    1. Huentelman, M. J. , Zubcevic, J. , Hernández Prada, J. A. , Xiao, X. , Dimitrov, D. S. , Raizada, M. K. , & Ostrov, D. A. (2004). Structure‐based discovery of a novel angiotensin‐converting enzyme 2 inhibitor. Hypertension, 44(6), 903–906.
    1. Imai, Y. , Kuba, K. , Rao, S. , Huan, Y. , Guo, F. , Guan, B. , … Penninger, J. M. (2005). Angiotensin‐converting enzyme 2 protects from severe acute lung failure. Nature, 436(7047), 112–116.
    1. Ishiyama, Y. , Gallagher, P. E. , Averill, D. B. , Tallant, E. A. , Brosnihan, K. B. , & Ferrario, C. M. (2004). Upregulation of angiotensin‐converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension, 43(5), 970–976.
    1. Klimas, J. , Olvedy, M. , Ochodnicka‐Mackovicova, K. , Kruzliak, P. , Cacanyiova, S. , Kristek, F. , … Ochodnicky, P. (2015). Perinatally administered losartan augments renal ACE2 expression but not cardiac or renal Mas receptor in spontaneously hypertensive rats. Journal of Cellular and Molecular Medicine, 19(8), 1965–1974. 10.1111/jcmm.12573
    1. Kuba, K. , Imai, Y. , Rao, S. , Gao, H. , Guo, F. , Guan, B. , … Penninger, J. M. (2005). A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus‐induced lung injury. Nature Medicine, 11(8), 875–879.
    1. Li, G. , & De Clercq, E . (2020). Therapeutic options for the 2019 novel coronavirus (2019‐nCoV). Nat Rev Drug Discov. 10.1038/d41573-020-00016-0. [Epub ahead of print].
    1. Li, W. , Moore, M. J. , Vasilieva, N. , Sui, J. , Wong, S. K. , Berne, M. A. , … Farzan, M. (2003). Angiotensin‐converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature, 426(6965), 450–454.
    1. Lu, R. , Zhao, X. , Li, J. , Niu, P. , Yang, B. , Wu, H. , et al. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet. 10.1016/S0140-6736(20)30251-8 [Epub ahead of print].
    1. Luo, H. , Tang, Q. L. , Shang, Y. X. , Liang, S. B. , Yang, M. , Robinson, N. , & Liu, J. P. (2020). Can Chinese medicine be used for prevention of Corona virus disease 2019 (COVID‐19)? A review of historical classics, research evidence and current prevention programs. Chinese Journal of Integrative Medicine. 10.1007/s11655-020-3192-6 [Epub ahead of print].
    1. Mahase, E. (2020). Coronavirus covid‐19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ. 10.1136/bmj.m641
    1. McIntyre, M. , Caffe, S. E. , Michalak, R. A. , & Reid, J. L. (1997). Losartan, an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension. Pharmacology & Therapeutics, 74(2), 181–194.
    1. Michel, N. , Allespach, I. , Venzke, S. , Fackfmicheller, O. T. , & Keppler, O. T. (2005). The Nef protein of human immunodeficiency virus establishes superinfection immunity by a dual strategy to downregulate cell‐surface CCR5 and CD4. Current Biology, 15(8), 714–723.
    1. Patel, A. , Jernigan, D. B. , & 2019‐nCoV CDC Response Team . (2020). Initial public health response and Interim clinical guidance for the 2019 Novel Coronavirus Outbreak—United States, December 31, 2019‐February 4, 2020. MMWR Morbidity and Mortality Weekly Report, 69(5), 140–146. 10.15585/mmwr.mm6905e1
    1. Phadke, M. , & Saunik, S. (2020). Rapid response: Use of angiotensin receptor blockers such as Telmisartan, Losartsan in nCoV Wuhan Corona Virus infections—Novel mode of treatment. Response to the emerging novel coronavirus outbreak. BMJ 2020, 368, m406. 10.1136/bmj.m406
    1. Prabakaran, P. , Xiao, X. , & Dimitrov, D. S. (2004). A model of the ACE2 structure and function as a SARS‐CoV receptor. Biochemical and Biophysical Research Communications, 314(1), 235–241.
    1. Santos, R. A. , Simoes e Silva, A. C. , Maric, C. , Silva, D. M. , Machado, R. P. , de Buhr, I. , … Walther, T. (2003). Angiotensin‐(1‐7) is an endogenous ligand for the G protein‐coupled receptor Mas. Proceedings of the National Academy of Sciences of the United States of America, 100(14), 8258–8263.
    1. Smyth, L. J. , Cañadas‐Garre, M. , Cappa, R. C. , Maxwell, A. P. , & McKnight, A. J. (2019). Genetic associations between genes in the renin–angiotensin–aldosterone system and renal disease: A systematic review and meta‐analysis. BMJ Open, 9(4), e026777. 10.1136/bmjopen-2018-026777
    1. Sun, M. L. , Yang, J. M. , Sun, Y. P. , & Su, G. H. (2020). Inhibitors of RAS might be a good choice for the therapy of COVID‐19 pneumonia. Zhonghua Jie He He Hu Xi Za Zhi, 43(0), E014. 10.3760/cma.j.issn.1001-0939.2020.0014 [Epub ahead of print]. Chinese.
    1. Tseng, C. T. , Sbrana, E. , Iwata‐Yoshikawa, N. , Newman, P. C. , Garron, T. , Atmar, R. L. , … Couch, R. B. (2012). Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One, 7(4), e35421. 10.1371/journal.pone.0035421
    1. Turner, A. J. , Hiscox, J. A. , & Hooper, N. M. (2004). ACE2: from vasopeptidase to SARS virus receptor. Trends in Pharmacological Sciences, 25(6), 291–294.
    1. Wan, Y. , Shang, J. , Graham, R. , Baric, R. S. , & Li, F. (2020). Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade‐long structural studies of SARS. J Virol. 10.1128/JVI.00127-20 [Epub ahead of print].
    1. World Health Organization . 2019. Coronavirus disease (COVID‐19) outbreak.
    1. Yu, C. M. , Wong, R. S. , Wu, E. B. , Kong, S. L. , Wong, J. , Yip, G. W. , … Sung, J. J. (2006). Cardiovascular complications of severe acute respiratory syndrome. Postgraduate Medical Journal, 82(964), 140–144.
    1. Zhang, L. , & Liu, Y. (2020). Potential Interventions for Novel Coronavirus in China: A systematic review. Journal of Medical Virology. 10.1002/jmv.25707 [Epub ahead of print].

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する